Medikamentöse Therapie von Gliomen

Die kombinierte Radiochemotherapie gewinnt bei Gliomen zunehmend an Bedeutung. Der Beitrag fasst die relevanten Studien sowohl nach der alten WHO Klassifikation von 2007 als auch nach der neuen Klassifikation zusammen. Dazu gibt er einen Ausblick auf eine neue, nebenwirkungsarme Therapieoption.

• Literatur

• 1 van den Bent MJ. Afra D. de Witte O. et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366: 985-990
• 2 Buckner JC. Shaw EG. Pugh SL. et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. New Engl J Med 2016; 374: 1344-1355
• 3 Wick W. Hartmann C. Engel C. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880
• 4 Cairncross G. Wang M. Shaw E. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31: 337-343
• 5 van den Bent MJ. Brandes AA. Taphoorn MJ. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-350
• 6 van den Bent MJ. Erridge S. Vogelbaum MA. et al. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 19/19q co-deletion: An intergroup trial. J Clin Oncol 2015 34. abstr LBA2000
• 7 Stupp R. Mason WP. van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 352: 987-996
• 8 Chinot OL. de La Motte Rouge T. Moore N. et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Therap 2011; 28: 334-340
• 9 Wick W. Platten M. Meisner C. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-715
• 10 Perry JR. Laperriere N. O’Callaghan CJ. et al. A phase III randomized trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma. J Clin Oncol 34, 2016 (suppl; abstr LBA2)
• 11 Chinot OL. de La Motte Rouge T. Moore N. et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Therap 2011; 28: 334-340
• 12 Herrlinger U. Schafer N. Steinbach JP. et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016; 34: 1611-1619
• 13 Wick W. Brandes AA. Gorlia T. et al. EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. J Clin Oncol 34, 2016 (suppl; abstr 2001)
• 14 Stupp R. Taillibert S. Kanner AA. et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 2015; 314: 2535-2543